Brief: Race Oncology Receives Positive Guidance On Zantrene Via Pre-Ind Meeting With Us FDA
23/11/2022 01:20
Nov 23 (Reuters) - Race Oncology Ltd RAC.AX :
* RECEIVES POSITIVE GUIDANCE ON ZANTRENE VIA PRE-IND MEETING
WITH
US FDA
Source text for Eikon: ID:nASX4DRKJm
Further company coverage: RAC.AX
Recent news on Racura Oncology
See all newsAustralia's Racura Oncology jumps most in a month after raising $24 million
Brief: Racura Oncology Says Emerging Companies Specialist Invests In Racura
Brief: Racura Oncology Announces Positive Safety Review Committee Recommendation In Ongoing Cpacs Clinical Trial
Australia's Racura Oncology gains on Purdue University cancer study collab
Brief: Racura Oncology Receives Governance Approval For Harness-1 Phase 1 Trial Of Rc220